India, June 1 -- image credit- shutterstock

A rising obese and diabetic population in India has triggered a rat race for pharma companies to launch GLP-1 products. GLP-1 refers to a broader category of products, and these include Liraglutide, Tirzepatide, and Semaglutide, as well as Dulaglutide, among others. Some of these medications have lost their patents and are widely available in India, while others, such as Dulaglutide and Tirzepatide, remain under patent protection.

The race to launch multiple brands

India's generic market seems to have unlimited potential, if the spurt in the generic drug launches is any indication. The companies which have launched their generic semaglutide products are expected to have a meaningful early-mov...